Review

1,8-naphthyridine derivatives: an updated review on recent advancements of their myriad biological activities

Department of Chemistry, Birla Institute of Technology & Science, Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Hyderabad, 500078, Telangana, India

Search for more papers by this author

Adinarayana Nandikolla

Department of Chemistry, Birla Institute of Technology & Science, Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Hyderabad, 500078, Telangana, India

Search for more papers by this author

Sankaranarayanan Murugesan

Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science Pilani, Pilani Campus, Pilani, 333031, Rajasthan, India

Search for more papers by this author

Venkata GCS Kondapalli

*Author for correspondence: Tel.: +91 406 630 3527;

E-mail Address: kvgc@hyderabad.bits-pilani.ac.in

https://orcid.org/0000-0002-2319-8297

Department of Chemistry, Birla Institute of Technology & Science, Pilani, Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Hyderabad, 500078, Telangana, India

Search for more papers by this author

Published Online:14 Jul 2021https://doi.org/10.4155/fmc-2021-0086

View article

Abstract

Among all nitrogen-containing heterocycles, the 1,8-naphthyridine scaffold has recently gained an immense amount of curiosity from numerous researchers across fields of medicinal chemistry and drug discovery. This new attention can be ascribed to its versatility of synthesis, its reactiveness and the variety of biological activities it has exhibited. Over the past half-decade, numerous diverse biological evaluations have been conducted on 1,8-naphthyridine and its derivatives in a quest to unravel novel pharmacological facets to this scaffold. Its potency to treat neurodegenerative and immunomodulatory disorders, along with its anti-HIV, antidepressant and antioxidant properties, has enticed researchers to look beyond its broad-spectrum activities, providing further scope for exploration. This review is a consolidated update of previous works on 1,8-naphthyridines and their analogs, focusing on the past 5 years.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Allen CFH. The naphthyridines. Chem. Rev. 47(2), 275–305 (1950).
Medline CASGoogle Scholar
2. Paudler WW, Kress TJ. The naphthyridines. Adv. Heterocycl. Chem. 11(1), 123–175 (1970).
Medline CASGoogle Scholar
3. Koller G. Über das 1.8-naphthyridin. Ber. Dtsch. Chem. Ges. 60(8), 1918–1920 (1927).
Google Scholar
4. Ikekawa N. Studies on naphthyridines. I. Synthesis of 1,6-naphthyridine. Chem. Pharm. Bull. 6(3), 263–269 (1958).
Medline CASGoogle Scholar
5. Ikekawa N. Studies on naphthyridines. III. Syntheses of 2,10-diazaanthracene and 1, 7-naphthyridine. Chem. Pharm. Bull. 6(4), 401–404 (1958).
Medline CASGoogle Scholar
6. Albert A. 355. Naphthyridines: ionization constants and spectra of four parent substances. J. Chem. Soc. 1960, 1790–1793 (1960).
Google Scholar
7. Ikekawa N. Studies on naphthyridines. II. Synthesis of 2,7-naphthyridine. Chem. Pharm. Bull. 6(3), 269–272 (1958).
Medline CASGoogle Scholar
8. Giacomello G, Gualtieri F, Riccieri FM, Stein ML. Synthesis of 2,6-naphthyridine. Tetrahedron Lett. 6(16), 1117–1121 (1965).
Google Scholar
9. Rosita T, Taurins A. Synthesis of 2, 6-naphthyridine and some of its derivatives. Tetrahedron Lett. 6(31), 2737–2744 (1965).
Google Scholar
10. Anderson EC, Sneddon HF, Hayes CJ. A mild synthesis of substituted 1,8-naphthyridines. Green Chem. 21(11), 3050–3058 (2019). • Involves a novel synthetic procedure with high yield and facile reaction conditions.
CASGoogle Scholar
11. Gurjar VK, Pal D. Recent developments and multiple biological activities available with 1,8-naphthyridine derivatives: a review. Int. J. Pharm. Pharm. 11(1), 17–37 (2019).
CASGoogle Scholar
12. Madaan A, Verma R, Kumar V, Singh AT, Jain SK, Jaggi M. 1,8-naphthyridine derivatives: a review of multiple biological activities. Archiv der Pharmazie 348(12), 837–860 (2015).
Medline CASGoogle Scholar
13. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 5(5), 1063–1065 (1962).
CASGoogle Scholar
14. Popiołek L, Monika G. The impact of modifying the chemical structure of nalidixic acid on the antimicrobial activity of its derivatives: a review. IRJPAC 7(4), 191–202 (2015).
CASGoogle Scholar
15. Brown EV. 1,8-Naphthyridines. I. Derivatives of 2-and 4-methyl-1,8-naphthyridines. J. Org. Chem. 30(5), 1607–1610 (1965).
CASGoogle Scholar
16. Litvinov VP. Chemistry and biological activities of 1,8-naphthyridines. Russ. Chem. Rev. 73(7), 637–670 (2004).
CASGoogle Scholar
17. Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med. Chem. 7(6), 685–709 (2007).
Medline CASGoogle Scholar
18. Paudler WW, Sheets RM. Recent developments in naphthyridine chemistry. Adv. Heterocycl. Chem. 33, 147–184 (1983).
CASGoogle Scholar
19. Fadda AA, El-Hadidy SA, Elattar KM. Advances in 1,8-naphthyridines chemistry. Synth. Commun. 45(24), 2765–2801 (2015).
CASGoogle Scholar
20. Ojha M, Yadav D, Kumar A, Dasgupta S, Yadav R. 1,8-naphthyridine derivatives: a privileged scaffold for versatile biological activities. Mini Rev. Med. Chem. 21(5), 576–591 (2021).
MedlineGoogle Scholar
21. Paudler WW, Kress TJ. Naphthyridine chemistry. V. One-step synthesis of 1,8-naphthyridines. J. Org. Chem. 32(3), 832–833 (1967).
CASGoogle Scholar
22. Hamada Y, Takeuchi I. Studies on the syntheses and reaction of nitrogen-containing heterocyclic compounds centered the naphthyridines. Yakugaku Zasshi. 120(2), 206–223 (2000).
Medline CASGoogle Scholar
23. Litvinov VP, Roman SV, Vladimir DD. Naphthyridines. Structure, physicochemical properties and general methods of synthesis. Russ. Chem. Rev. 69(3), 201–220 (2000).
CASGoogle Scholar
24. Ayoub AI, Saleh MY. Synthesis, identification and antibacterial evaluation of some 1,3,4-oxadiazoles derivative on 1,8-naphthyridine ring. World J. Pharm. Pharm. Sci. 6(9), 302–311 (2017).
CASGoogle Scholar
25. Makhanya TR, Gengan RM, Ata A. Synthesis and biological evaluation of novel fused indolo [3,2-c][1,8] naphthyridine derivatives as potential antibacterial agents. Synth. Commun. 49(6), 823–835 (2019).
CASGoogle Scholar
26. Akula M, Yogeeswari P, Sriram D, Jha M, Bhattacharya A. Synthesis and anti-tubercular activity of fused thieno-/furo-quinoline compounds. RSC Adv. 6(52), 46073–46080 (2016).
CASGoogle Scholar
27. Patil PT, Warekar PP, Patil KT et al. A simple and efficient one-pot novel synthesis of pyrazolo [3,4-b][1,8] naphthyridine and pyrazolo [3,4-d] pyrimido [1,2-a] pyrimidine derivatives as anti-inflammatory agents. Res. Chem. Intermed. 44, 1119–1130 (2018).
CASGoogle Scholar
28. Behalo MS, Mele G. Synthesis and evaluation of pyrido [2,3-d] pyrimidine and 1,8-naphthyridine derivatives as potential antitumor agents. J. Heterocycl. Chem. 54(1), 295–300 (2016).
Google Scholar
29. Makhanya TR, Gengan RM, Pandian P, Chuturgoon AA, Tiloke C, Atar A. Phosphotungstic acid catalyzed one pot synthesis of 4, 8, 8-trimethyl-5-phenyl-5, 5a, 8, 9-tetrahydrobenzo [b][1,8] naphthyridin-6 (7H)-one derivatives and their biological evaluation against A549 lung cancer cells. J. Heterocycl. Chem. 55(5), 1193–1204 (2018).
CASGoogle Scholar
30. Zhao XZ, Smith SJ, Maskell DP et al. HIV-1 integrase strand transfer inhibitors with reduced susceptibility to drug resistant mutant integrases. ACS Chem. Biol. 11(4), 1074–1081 (2016).
Medline CASGoogle Scholar
31. Paudler WW, Thomas KJ. The Skraup syntheses and NMR spectra of some methyl naphthyridines. J. Heterocycl. Chem. 4(2), 284–289 (1967).
CASGoogle Scholar
32. Sakram B, Ashok K, Rambabu S, Sonyanaik B, Ravi D. A novel and efficient synthesis of 3-iodo substituted 1,8-naphthyridines by electrophilic cyclization of 2-amino nicotinaldehyde and their antimicrobial activity. Russ. J. Gen. Chem. 87(8), 1794–1799 (2017).
CASGoogle Scholar
33. Sakram B, Ravi D, Ashok K, Rambabu S, Sonyanaik B, Kurumanna A. An efficient microwave-assisted synthesis of novel 2-{4-[(3-aryl-1,8-naphthyridin-2-yl) amino] phenyl}-1H-benzo [de] isoquinoline-1, 3 (2H)-diones and their antimicrobial activity. Russ. J. Gen. Chem. 88, 780–788 (2018).
CASGoogle Scholar
34. Sakram B, Sonyanaik B, Ashok K et al. Eco-friendly synthesis of 1,8-naphthyridine 5-aryl-1, 3, 4-oxadiazole derivatives under solvent-free solid-state conditions and their antimicrobial activity. Res. Chem. Intermed. 43, 1881–1892 (2017).
CASGoogle Scholar
35. Sakram B, Kurumanna A, Ashok A, Rambabu S, Ravi V, Kumar BS. Synthesis and antibacterial activity of novel 3-N-substituted 1,8-naphthyridin-2 (1 H)-ones. Russ. J. Gen. Chem. 89, 2534–2543 (2019).
CASGoogle Scholar
36. Sakram B, Madhu P, Sonyanaik B, Rambabu S, Ravi D, Kurumanna A. Ferric chloride-catalyzed synthesis of 2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate derivatives and their biological evaluation. Russ. J. Gen. Chem. 88, 1224–1227 (2018).
CASGoogle Scholar
37. Bhatt S, Bagal SM, Butola S, Dhar AK, Mahesh R. Antidepressant- and anxiolytic-like effect of novel 5-hydroxytryptamine3 receptor antagonist 2-[4-(3-chlorophenyl) piperazin-1-yl]-1,8-naphthyridine-3-carboxylic acid (7e)-: an approach using rodent behavioral antidepressant and anxiolytic test battery. Int. J. Nutr. Pharmacol. Neurol. Dis. 6(2), 81–89 (2016).
CASGoogle Scholar
38. Sachdeva S, Bhatia S, Mittal A, Sinha M. Synthesis, evaluation and in silico studies of 1,8-naphthyridine derivatives against antimicrobial activity. J. Appl. Pharm. Sci. 5(7), 53–59 (2015).
CASGoogle Scholar
39. Mohammed AAM, Suaifan GARY, Shehadeh MB, Okechukwu PN. Design, synthesis, and biological evaluation of 1,8-naphthyridine glucosamine conjugates as antimicrobial agents. Drug Dev. Res. 80(1), 179–186 (2019).
Medline CASGoogle Scholar
40. Arab HA, Faramarzi MA, Samadi N, Irannejad H, Foroumadi A, Emami S. New 7-piperazinylquinolones containing (benzo [d] imidazol-2-yl) methyl moiety as potent antibacterial agents. Mol. Divers. 22(4), 815–825 (2018).
Medline CASGoogle Scholar
41. Gao LZ, Xie YS, Li T, Huang WL, Hu GQ. Synthesis and antibacterial activity of novel [1,2,4] triazolo [3,4-h][1,8] naphthyridine-7-carboxylic acid derivatives. Chin. Chem. Lett. 26(1), 149–151 (2015).
CASGoogle Scholar
42. Kim T, Park SJ, Chong YP et al. Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. Diagn. Microbiol. Infect. Dis. 86(2), 181–183 (2016).
Medline CASGoogle Scholar
43. Popiolek L, Biernasiuk A. New nalidixic acid-1,3-thiazolidin-4-one hybrids: design, synthesis and in vitro antimicrobial activity. Phosphorus Sulfur Silicon Relat. Elem. 192(1), 23–27 (2017).
CASGoogle Scholar
44. Popiolek L, Biernasiuk A, Malm A. Synthesis and in vitro antimicrobial activity of nalidixic acid hydrazones. J. Heterocycl. Chem. 53(5), 1589–1594 (2016).
CASGoogle Scholar
45. Marinov M, Kostova I, Naydenova E, Stoyanov N. Synthesis and antimicrobial activity of 1,8-naphthalimide derivatives of nalidixic acid. J. Chem. Technol. Metall. 54(6), 1146–1156 (2019).
CASGoogle Scholar
46. Vijaya Bhasker G, Laxminarayana E, Latha A, Chary MT. Synthesis and antibacterial activity of 2-((3/4-(1,8-naphthyridin-2-Yl)phenoxy)methyl)-N-phenylbenzamide derivatives. Rasayan J. Chem. 10(4), 1521–1528 (2017).
Google Scholar
47. Ravi D, Rambabu S, Ashok K, Madhu P, Sakram B. An exceedingly mild, green synthesis of substituted N-3-diaryl-1,8-naphthyridin-2-amine derivatives and their antimicrobial activity. J. Heterocycl. Chem. 55(4), 957–963 (2018).
CASGoogle Scholar
48. Ayoub AI, Saleh MY. Synthesis of some new heterocyclic compound derivative from 2-chloro-3-formyl-1,8,-naphthyridine. Eur. Chem. Bull. 5(4), 151–156 (2016).
CASGoogle Scholar
49. Dharavath R, Boda S. A synthesis and biological screening of newly substituted 9-methyl-6-aryl-[1,2,4] triazolo [4,3-a][1,8] naphthyridines using chloranil. Synth. Commun. 49(14), 1741–1749 (2019).
CASGoogle Scholar
50. Gohil JD, Patel HB, Patel MP. Synthesis and evaluation of new chromene based [1,8] naphthyridines derivatives as potential antimicrobial agents. RSC Adv. 6(78), 74726–74733 (2016).
CASGoogle Scholar
51. Peraman R, Varma RV, Reddy YP. Re-engineering nalidixic acid's chemical scaffold: a step towards the development of novel anti-tubercular and anti-bacterial leads for resistant pathogens. Bioorg. Med. Chem. Lett. 25(19), 4314–4319 (2015).
Medline CASGoogle Scholar
52. Banoth S, Perugu S, Boda S. Green synthesis of fused imidazo [1,2-a][1,8] naphthyridine derivatives catalyzed by DABCO under solvent-free solid-state conditions and their biological evaluation. J. Heterocycl. Chem. 55(3), 709–715 (2018). •• Describes a novel solvent-free condition for reaction, producing high yields.
CASGoogle Scholar
53. Sakram B, Ravi D, Raghupathi M, Kumar BS, Anantha Lakshmi PV. A facile greener synthesis, antimicrobial evaluation and molecular modelling of new 4-aryl-2-(3-(2-(trifluoromethyl) phenyl)-1,8-naphthyridin-2-yl) phthalazin-1 (2H)-one derivatives. Res. Chem. Intermed. 45, 2007–2022 (2019).
CASGoogle Scholar
54. Bhasker GV, Satyanarayana GV, Laxminarayana E, Latha A, Chary MT. Synthesis, antibacterial activity, and docking studies of some new 2-substituted-1,8-naphthyridine derivatives. Indian J. Heterocycl. Chem. 28(2), 227–242 (2018).
CASGoogle Scholar
55. Mogilaiah K, Venkanna Ch, Nageswara Rao A, Ramesh Babu H. Green synthesis, antibacterial and anti-inflammatory activities of 2-(2-substituted [1,8] naphthyridin-3-yl)-5-(substituted-2-thienyl)-1,3,4-oxadiazoles. Indian J. Chem. 56B, 670–676 (2017).
CASGoogle Scholar
56. Mogilaiah K, Nageswara Rao A, Jyothi S. Environmentally benign synthesis, antibacterial and anti-inflammatory activities of 3-aryl-1-{3-[2-(trifluoromethyl) phenyl][1,8] naphthyridin-2-yl}-1H-4-pyrazolecarbaldehydes. Indian J. Chem. 54B, 1355–1359 (2015).
CASGoogle Scholar
57. Gençer HK, Levent S, Acar Çevik U, Özkay Y, Ilgın S. New 1,4-dihydro [1,8] naphthyridine derivatives as DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 27(5), 1162–1168 (2017).
Medline CASGoogle Scholar
58. Omar FA, Abelrasoul M, Sheha MM, Hassan HY, Ibrahiem YM. Synthesis, antibacterial activity and molecular docking of substituted naphthyridines as potential DNA gyrase inhibitors. ChemistrySelect 3(9), 2604–2612 (2018).
CASGoogle Scholar
59. Ravi D, Ashok K, Rambabu S, Sakram B, Shyam P. A simple ‘green’ synthesis of novel bis (3-aryl-1,8-naphthyridin-2-yl) sulfanes and 2-(methylthio)-3-aryl-1,8-naphthyridines under microwave irradiation and conventional conditions. Russ. J. Gen. Chem. 88, 1232–1237 (2018).
CASGoogle Scholar
60. Mubarak S, Zia-ur-rehman M, Jamil N, Zaheer M, Arshad MN, Mohammad AA. Environment friendly synthesis of N'-(1,3-diphenylallylidene)-1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carbohydrazides: crystal structure and their anti-oxidant potential. Chem. Pharm. Bull. 67(11), 1191–1200 (2019).
Medline CASGoogle Scholar
61. Sonyanaik B, Sakram B, Shyam P, Madhu P, Govan M. Green synthesis and biological evaluation of novel fused 6-(2-chloro-4-fluorophenyl)-9-arylimidazo [1, 2-a][1,8] naphthyridine derivatives catalyzed by DABCO. Russ. J. Gen. Chem. 88, 1495–1501 (2018).
CASGoogle Scholar
62. Bhasker GV, Satyanarayana GV, Latha A, Laxminarayana E, Thirumala Chary M. Synthesis and antimicrobial activity of novel 1-[3-(1,8-naphthyridin-2-yl) phenyl]-3-arylurea derivatives. Asian J. Chem. 30(4), 771–774 (2018).
CASGoogle Scholar
63. Swamy JK, Kumar EJ, Kavitha S. Antimicrobial screening of 1,8-naphthyridin-fused ring containing N, O heterocyclic hybrids. Alochana Chakra Journal 9, 535–542 (2020).
Google Scholar
64. Sakram B, Kurumanna A, Ravi D, Madhu P, Narsaiah B, Ramesh M. Synthesis of new N-phenyl-3-aryl-1,8-naphthyridin-2-amines and 4-((3-aryl-1,8-naphthyridin-2-yl) amino) phenols and their biological and molecular docking studies. Chem. Data Collect. 25, 100313 (2020).
CASGoogle Scholar
65. Swamy JK, Kumar EJ, Kavitha S. Screening and biological evaluation of fluorinated 1,8-naphthyridinyl phthalazine-1,4-dithiones. High Technol. Lett. 26, 1246–1249 (2020).
Google Scholar
66. Badawneh M, Aljamal J. Synthesis and antitubercular activity of piperidine and morpholine 1,8 naphthyridine analogues. Int. J. Pharm. Pharm. Sci. 8(12), 252–257 (2016). • Research involves increasing antitubercular activity and eliminating toxicity.
CASGoogle Scholar
67. Markad SD, Kaur P, Kishore Reddy BK et al. Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments. Med. Chem. Res. 24, 2986–2992 (2015).
CASGoogle Scholar
68. Abd Allah OA, El-Saghier AM, Kadry AM, Seleem AA. Synthesis and evaluation of some novel curcumin derivatives as anti-inflammatory agents. Int. J. Pharm. Sci. Rev. Res. 32(1), 87–92 (2015).
Google Scholar
69. Fu F, Feng X, Wang JJ et al. Efficient synthesis and evaluation of antitumor activities of novel functionalized 1,8-naphthyridine derivatives. ACS Comb. Sci. 17(1), 24–31 (2015).
Medline CASGoogle Scholar
70. Jia XD, Wang S, Wang MH et al. Synthesis and in vitro antitumor activity of novel naphthyridinone derivatives. Chin. Chem. Lett. 28(2), 235–239 (2017).
CASGoogle Scholar
71. Duan Y, Xu S, Xiong H et al. Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents. Bioorg. Med. Chem. Lett. 28(3), 254–259 (2018).
Medline CASGoogle Scholar
72. Tang Q, Duan Y, Xiong H et al. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety. Eur. J. Med. Chem. 158, 201–213 (2018).
Medline CASGoogle Scholar
73. El-Hadidy SA, Selim YA. New synthetic approaches for cytotoxic activity of novel 1,8-naphthyridine derivatives. J. Heterocycl. Chem. 55(1), 103–114 (2018).
CASGoogle Scholar
74. Al-Romaizan AN, Jaber TS, Ahmed NS. Novel 1,8-naphthyridine derivatives: design, synthesis and in vitro screening of their cytotoxic activity against MCF7 cell line. Open Chem. 17(1), 943–954 (2019).
CASGoogle Scholar
75. Abu-Melha S. Synthesis and biological evaluation of some novel 1,8-naphthyridine derivatives. Acta Chim. Slov. 64(4), 919–930 (2017).
Medline CASGoogle Scholar
76. Bardasov IN, Alekseeva AY, Ershov OV, Mar'yasov MA. Antiproliferative activity of N-substituted 2, 4-diamino-5-Aryl-5,6,7,8,9,10-hexahydrobenzo [B][1,8] naphthyridine-3-carbonitriles. Pharm. Chem. J. 54, 459–461 (2020).
CASGoogle Scholar
77. Sudharshan Reddy S, Swamy JK, Kumar EJ, Kavitha S. In vitro anti-cancer evaluation and molecular modelling studies of 1,8-naphthyridine derivatives. High Technol. Lett. 26, 1163–1168 (2020).
Google Scholar
78. Xueyan H, Luo H, Zhang M et al. Synthesis and biological evaluation of 3-(1,3,4-oxadiazol-2-yl)-1,8-naphthyridin-4(1H)-ones as cisplatin sensitizers. MedChemComm. 9(11), 1949–1960 (2018). • Evaluates cisplatin sensitization activity in addition to antitumor activity.
MedlineGoogle Scholar
79. Wang H, Wang S, Cheng L et al. Discovery of imidazo [1,2-α][1,8] naphthyridine derivatives as potential HCV entry inhibitor. ACS Med. Chem. Lett. 6(9), 977–981 (2015).
Medline CASGoogle Scholar
80. Dhar AK, Mahesh R, Jindal A, Bhatt S. Piperazine analogs of naphthyridine-3-carboxamides and indole-2-carboxamides: novel 5-HT3 receptor antagonists with antidepressant-like activity. Arch. Pharm. Chem. Life Sci. 348(1), 34–45 (2015).
Medline CASGoogle Scholar
81. Husain A, Varshney MM, Parcha V, Ahmad A, Khan SA. Nalidixic acid Schiff bases: synthesis and biological evaluation. Lett. Drug Des. Discov. 15(1), 103–111 (2018).
CASGoogle Scholar
82. Ramos E, Romero A, Egea J, Marco-Contelles J, Del Pino J, De Los Riós C. Analysis of gene expression profiles of CR80, a neuroprotective 1,8-naphthyridine. Future Med. Chem. 10(11), 1289–1300 (2018).
CASGoogle Scholar
83. Malfitano AM, Laezza C, Bertini S et al. Immunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative. Biochimie 135, 173–180 (2017).
Medline CASGoogle Scholar
84. Datiane C, Oliveira-tintino DM, Relison S et al. Do 1,8-naphthyridine sulfonamides possess an inhibitory action against Tet (K) and MsrA efflux pumps in multiresistant Staphylococcus aureus strains? Microb. Pathog. 147, 104268 (2020).
MedlineGoogle Scholar
85. Yukawa T, Nakahata T, Okamoto R et al. Discovery of 1,8-naphthyridin-2-one derivative as a potent and selective sphingomyelin synthase 2 inhibitor. Bioorg. Med. Chem. 28(7), 115376 (2020). •• Recent, in-depth research on novel drugs for treating sphingomyelin synthase 2-related diseases.
Medline CASGoogle Scholar
86. Kumar GV, Dilipkumar P. Design, in silico studies, and synthesis of new 1,8-naphthyridine-3-carboxylic acid analogues and evaluation of their H1R antagonism effects. RSC Adv. 10(23), 13907–13921 (2020). •• Commendable research article on antihistaminic effect using in vivo model.
Google Scholar
87. U.S. Patent 9,598,407 B2. (2017).
Google Scholar
88. U.S. Patent 9,855,255 B1. (2018).
Google Scholar
89. U.S. Patent 2017/0368041 A1. (2017).
Google Scholar
90. U.S. Patent 2016/0317510 A1. (2016).
Google Scholar
91. U.S. Patent 10,239,875 B2. (2019).
Google Scholar
92. WO 2020/104436 Al. (2020).
Google Scholar
93. WO 2020/084648 A1. (2020).
Google Scholar
94. Konishi H, Okamoto K, Ohmori Y et al. An orally available, small-molecule interferon inhibits viral replication. Sci. Rep. 2(1), 259 (2012).
MedlineGoogle Scholar
95. Pandey G, Mishra A, Khamrai J. Asymmetric total synthesis of eburnamine and eucophylline: a biomimetic attempt for the total synthesis of leucophyllidine. Org. Lett. 19(12), 3267–3270 (2017).
Medline CASGoogle Scholar

Vol. 13, No. 18

Metrics

Downloaded 172 times

History

Received 26 March 2021

Accepted 21 June 2021

Published online 14 July 2021

Published in print September 2021

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download